A Phase 2 Study of Oral MKC-1 in Patients With Ovarian or Endometrial Cancer
Status:
Completed
Trial end date:
2012-01-01
Target enrollment:
Participant gender:
Summary
Patients will be treated with MKC-1, twice daily for 14 consecutive days every four weeks (a
cycle of MKC-1 chemotherapy), until disease progression or unacceptable toxicities. Patients
will be stratified to Arm A (ovarian cancer) or Arm B (endometrial cancer), and will receive
identical treatment regimens.